Supernus Pharmaceuticals (SUPN) Net Cash Flow Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) Net Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -1,020.00% |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.36 Bn | - | 21.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.29% |
| Dec 31, 2025 | -160.87% |
| Sep 30, 2025 | 139.72% |
| Jun 30, 2025 | 355.15% |
| Mar 31, 2025 | 499.18% |
| Dec 31, 2024 | 288.94% |
| Sep 30, 2024 | -129.05% |
| Jun 30, 2024 | 97.41% |
| Mar 31, 2024 | -103.16% |
| Dec 31, 2023 | -8.49% |
| Sep 30, 2023 | 213.47% |
| Jun 30, 2023 | -858.05% |
| Mar 31, 2023 | 520.75% |
| Dec 31, 2022 | -55.08% |
| Sep 30, 2022 | -629.52% |
| Jun 30, 2022 | 281.08% |
| Mar 31, 2022 | -165.83% |
| Dec 31, 2021 | -114.05% |
| Sep 30, 2021 | -27.06% |
| Mar 31, 2021 | -174.34% |